Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(?) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(?) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.

Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

Abstract: Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.

Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.

Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: Provided is a labeled fatty acid derivative for diagnostic imaging that enables quantification of fatty acid metabolic activity in the heart muscle. [Means for Solution] The present inventors have conducted intensive investigations on a method that enables quantification of fatty acid metabolic activity and thus have found that a labeled fatty acid derivative typified by 3-{[(5Z)-3-[18F]fluorotetradeca-5-en-1-yl]sulfanyl}propanoic acid or a salt thereof has excellent accumulation to the heart muscle and thus enables imaging of fatty acid metabolic activity by positron emission tomography (PET). Therefore, the labeled fatty acid derivative of the present invention can be used as a radiolabeled tracer for rapid and non-invasive quantification of fatty acid metabolic activity in the heart muscle, diagnostic imaging of heart disease typified by an ischemic heart disease, diagnostic imaging of the therapeutic effect of a therapeutic drug for heart disease, and the like.

Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.

Abstract: An object of the present invention is to provide a cell therapy that is expected to be useful as an angiogenic therapy for a peripheral vascular disease such as critical lower limb ischemia. Specifically, the object is to provide a pericyte having high angiogenic potential and a method for producing the same. A pericyte introduced a bFGF gene and a method for producing the same are provided.

Abstract: An electrocardiogram analysis assistance device (10) including: an analysis waveform acquisition unit (11C) that acquires waveform data in an electrocardiogram for analysis; an analysis waveform select and extract unit (11D) that selects and extracts waveform data of a predetermined first period from the waveform data acquired by the analysis waveform acquisition unit (11C) as analysis divided waveform data; an intermediate information acquisition unit (11I) that acquires intermediate information generated in a middle layer of a peak estimation model (13C) and indicating a shape feature of a peak contained in the analysis divided waveform data by inputting the analysis divided waveform data selected and extracted by the analysis waveform select and extract unit (11D) into the peak estimation model (13C); and a classification unit (11J) that classifies a type of the waveform of the electrocardiogram for analysis using the intermediate information acquired by the intermediate information acquisition unit (11I).

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

Abstract: An electrocardiogram analysis assistance device (10) including: a peak estimation model (13C) employing waveform data of partial segments of waveform data in an electrocardiogram as input information and employing peak information indicating whether or not a predetermined type of peak related to electrocardiogram analysis is present as output information; an analysis waveform acquisition unit (11C) that acquires waveform data in an electrocardiogram for analysis; an analysis waveform select and extract unit (11D) that selects and extracts waveform data of a predetermined first period from the waveform data acquired by the analysis waveform acquisition unit (11C) as analysis divided waveform data, while each time shifting a predetermined shift period that is a shorter period than the first period; and a derivation unit (11E) that derives the peak information by inputting the analysis divided waveform data selected and extracted by the analysis waveform select and extract unit (11D) into the peak estimation mod

Abstract: An object of the present invention is to provide an antisense guide RNA for editing a polyadenylation signal sequence of a target RNA and a nucleic acid that encodes the guide RNA, which are expected to control expression of the target RNA with high efficiency. The present inventors have intensively examined technologies for controlling expression of a target RNA with high efficiency, thereby completing the present invention by discovering a guide RNA for ADAR-dependent editing of the target RNA, including an antisense region complementary to a portion of the target RNA including a polyadenylation signal sequence.

Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Abstract: An arrhythmic state detection assisting device includes an acquisition unit, a derivation unit and an estimation unit. The acquisition unit acquires image information obtained by capturing an image of a predetermined part of a subject with an image capture device that captures a color moving image. The derivation unit derives a variance value, for a predetermined interval, of periods of a periodic change in a green luminance component in the image information acquired by the acquisition unit. As the variance value derived by the derivation unit becomes greater, the estimation unit estimates a higher likelihood that an arrhythmia is occurring in the subject.